Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.

Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an update. On December 30, 2025, Ultragenyx Pharmaceutical announced it had completed the ...

If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIaNOVATO, Calif., Dec. 30, 2025 ...

Murphy’s law worked hard in 2025.A year full of “what else can go wrong”, and then the wrong proceeds to make its way in, ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...

We tested highly rated smart locks that feature connectivity, changeable codes, and fingerprint readers. Find out which ones ...

Sri Lanka’s Panasian Power said its 5MW ground-mounted solar project at Baddegama, Galle was connected to Galle Grid ...

Sri Lanka Customs has earned 870 billion rupees from vehicle imports, with year end collections expected to be around 2,545 ...

Microsoft didn’t release a major new version of Windows in 2025, but it did deliver a lot of significant updates. Here's my ...

More landlord licensing, higher fees for breaking bylaws and updated carbon monoxide detector rules are coming to Brampton at ...

A simple software method to increase the duty-cycle resolution in a digital pulse width modulation (DPWM)-controlled power ...